SIRT3 and neoplasm: Interestingly, this was not the case in the p53 heterozygous background, where Sirt3−/−; p53+/− mice did not benefit from CR (Sirt3−/−p53+/−: CR vs. ctrl p = 0.4 survival / CR vs. ctrl p = 0.1 tumor incidence) (Figures 3C,D and Supplementary Table 1).